Sunitinib

Deciphera Pharmaceuticals, Inc. Announces Publication of INTRIGUE Phase 3 Clinical Study Results in Journal of Clinical Oncology

Retrieved on: 
Wednesday, August 10, 2022
Research, FDA, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, III, Union, KIT, NDA, Journal of Clinical Oncology, United Kingdom, ORR, Cancer, GIST, Toxicity, Patient, Adult, Exon, Skin, PDGFRA, ITT, NASDAQ, Leisure, Journal, PFS, LinkedIn, Sunitinib, Progression-free survival, Food, Pharmaceutical industry, Twitter

These full Phase 3 INTRIGUE study results continue to deepen our understanding of QINLOCK and its place in the GIST treatment landscape, said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera.

Key Points: 
  • These full Phase 3 INTRIGUE study results continue to deepen our understanding of QINLOCK and its place in the GIST treatment landscape, said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera.
  • INTRIGUE is an international, multi-center study conducted in 122 active sites across 22 countries, where 453 patients with second-line GIST were randomized to receive ripretinib (n=226) or sunitinib (n=227).
  • Patient reported outcome measures also showed a more favorable tolerability profile for patients receiving ripretinib compared to patients receiving sunitinib.
  • Clinical activity of ripretinib in patients with advanced gastrointestinal stromal tumor harboring heterogenous KIT/PDGFRA mutations in the phase 3 INVICTUS study.

HUTCHMED Highlights First Presentation of Results of the SAVANNAH Global Phase II Trial of Savolitinib plus TAGRISSO® at the 2022 WCLC Annual Meeting

Retrieved on: 
Wednesday, July 13, 2022
PRCC, Neoplasm, Lung, LinkedIn, Pemetrexed, Hong Kong Stock Exchange, Patient, Program, Colorectal cancer, AIM, AstraZeneca, HIV disease progression rates, Woman, Cancer, U.S. Securities and Exchange Commission, New Drug Application, Gene amplification, Conference, Hereditary diffuse gastric cancer, Society, Pharmacokinetics, HCM, Sunitinib, Mutation, GC, American Society of Clinical Oncology, WCLC, TKI, Survival, Dor, Private Securities Litigation Reform Act, ORR, Forward-looking statement, PD-L1, Squamous cell carcinoma, Adenocarcinoma, Prevalence, Disease, Safety, GEJ, Lung cancer, COVID-19, PFS, Therapy, Growth, Man, MET, EGFR, Kidney, NSCLC, Medical imaging, Pharmaceutical industry, Lancet, Savolitinib, RCC

In 2011, following its discovery and initial development by HUTCHMED, AstraZeneca and HUTCHMED entered a global licensing and collaboration agreement to jointly develop and commercialize savolitinib.

Key Points: 
  • In 2011, following its discovery and initial development by HUTCHMED, AstraZeneca and HUTCHMED entered a global licensing and collaboration agreement to jointly develop and commercialize savolitinib.
  • Joint development of savolitinib in China is led by HUTCHMED, while AstraZeneca leads development outside of China.
  • Based on results of the TATTON and SAVANNAH studies below, several Phase III studies of savolitinib in combination with TAGRISSO have been initiated, including SACHI, SANOVO and SAFFRON.
  • This trial follows multiple Phase II studies that have been conducted in Asia to study savolitinib in MET-driven GC patients, including VIKTORY25.

Gastric Cancer Drugs Global Market Research Report 2022: Doxorubicin Hydrochloride, Sunitinib, Docetaxel, Mitomycin, Fluorouracil, Imatinib, Trastuzumab - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 30, 2022
Pharmaceutical, Health, Oncology, Smoking, FDA, Fluorouracil, Government, Doxorubicin, Patient, European Medicines Agency, Renal cell carcinoma, Administration, Blas, Docetaxel, NDAS, American Institute for Cancer Research, Sunitinib, Population, Man, Growth, Adenocarcinoma, GEJ, Obesity, EMA, RCC, GIST, Risk, Woman, USFDA, Good manufacturing practice, Stomach, Stomach cancer, CGMP, Mitomycins, Trastuzumab, Safety, Pain scale, Method, Hospital, Medical imaging, Pharmaceutical industry, Dietary supplement

The "Gastric Cancer Drugs Global Market Report 2022, Type, End User, Route of Administration" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Gastric Cancer Drugs Global Market Report 2022, Type, End User, Route of Administration" report has been added to ResearchAndMarkets.com's offering.
  • The gastric cancer drugs market consists of sales of drugs for gastric cancer.
  • The main types of gastric cancer drugs are doxorubicin hydrochloride, sunitinib, docetaxel, mitomycin, fluorouracil, imatinib and trastuzumab.
  • Increase in number of cases in gastric cancer will drive the market for gastric cancer drugs.

Global Kidney Cancer Market Forecast to 2028 - Abbvie, Bayer Pharma, Merck & Co, GlaxoSmithKline, and Pfizer Are Dominating the Industry - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 2, 2022
Pharmaceutical, Health, Oncology, Woman, MRP, American Cancer Society, Cryotherapy, Immunotherapy, Benign tumor, US, Man, US Foods, GlaxoSmithKline, Squamous cell carcinoma, Food, Merck & Co., RCC, Cancer, Smoking, Biopsy, Wilms' tumor, US FDA, AbbVie, Growth, CT, Adoption, Diagnosis, Kidney cancer, Renal cell carcinoma, Magnetic resonance imaging, Pfizer, Drinking, Sunitinib, MRI, CAGR, Pharmaceutical industry, Cabozantinib

The global kidney cancer market is anticipated to grow at a substantial CAGR of 6.2% during the forecast period.

Key Points: 
  • The global kidney cancer market is anticipated to grow at a substantial CAGR of 6.2% during the forecast period.
  • Reduced physical activity and excessive smoking and drinking are also a factor that is driving the kidney cancer market.
  • The global kidney cancer market is segmented based on the cancer type, cancer cell, diagnosis, and therapy.
  • The major companies serving the global kidney cancer market include Abbvie Inc., Bayer Pharma AG, Merck & Co., GlaxoSmithKline plc, and Pfizer Inc.

Global Sunitinib Malate Market Report to 2027 - Featuring Active Biotech, Astellas Pharma, AstraZeneca and Bristol Myers Squibb Among Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 1, 2022
Seniors, Biotechnology, Pharmaceutical, Oncology, Health, Chemicals, Plastics, Consumer, Manufacturing, Sunitinib, Pancreatic neuroendocrine tumor, Pancreatic cancer, Growth, Prevalence, Degenerative disease, GIST, CAGR, Gastrointestinal stromal tumor, Pharmaceutical industry

The global sunitinib malate market is anticipated to grow at a considerable CAGR during the forecast period.

Key Points: 
  • The global sunitinib malate market is anticipated to grow at a considerable CAGR during the forecast period.
  • The increasing prevalence of the gastrointestinal disorder is a creating demand for sunitinib malate market.
  • Expanding geriatric populace coupled with rising cases of pancreatic cancer are further supporting the growth of the global sunitinib malate market.
  • Based on application, the sunitinib malate market is segmented into pancreatic neuroendocrine tumors, advanced kidney cancer, gastrointestinal stromal tumor (GIST), and other.

IDEAYA Biosciences Appoints Catherine Mackey, Ph.D., to its Board of Directors

Retrieved on: 
Wednesday, April 6, 2022
Theta, Genetic distance, Therapy, Biomarker, Crizotinib, Sunitinib, NASDAQ, Multimedia, Board, Rady Children's Hospital, IND, Texas Institute for Genomic Medicine, Research, Hospital, Precision medicine, Board of directors, PKC, PARG, View, YM Biosciences, Industry, Genomics, Pfizer, Director, U.S. Securities and Exchange Commission, Institute, Trillium, Drug discovery, Development, SAN, Annual report, Legacy Fighting Alliance in 2018, Pharmaceutical industry, Palbociclib, Axitinib

SOUTH SAN FRANCISCO, Calif., April 6, 2022 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced the appointment of Catherine Mackey, Ph.D., to its Board of Directors. 

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., April 6, 2022 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced the appointment of Catherine Mackey, Ph.D., to its Board of Directors.
  • Dr. Mackey brings over 30 years of life sciences research, development and operational experience to IDEAYA.
  • Dr. Mackey also has considerable relevant experience as a Board Director of several public and private companies.
  • IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality which represents an emerging class of precision medicine targets.

Graybug Vision to Host Virtual R&D Day on March 30, 2022

Retrieved on: 
Monday, March 21, 2022
Private Securities Litigation Reform Act, Retina, University, Form 10-K, MA, Investor, Pediatric ophthalmology, Forward-looking statement, ID, Clinical research, Annual report, University of California, Irvine School of Medicine, University of California, SEC, Doctor of Philosophy, Sunitinib, Webcast, Medical director, U.S. Securities and Exchange Commission, Johns Hopkins School of Medicine, Technology, Karger Publishers, VEGF, Reno 1868 FC, Institute, COVID-19, MBA, University of Nevada, Reno School of Medicine, GLOBE, Fellow, Disease management, Division, CHOC, Security (finance), Pharmaceutical industry, Medicine, Ophthalmology, MD

BALTIMORE, March 21, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced that it will host a virtual Investor R&D Day from 11 a.m. - 12:45 p.m.

Key Points: 
  • BALTIMORE, March 21, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced that it will host a virtual Investor R&D Day from 11 a.m. - 12:45 p.m.
  • Additionally, Graybug will provide a strategic outlook.
  • Attendees may also participate by dialing (844) 955-2748 (domestic) or (929) 517-0407 (international) and entering the conference ID# 9785187.
  • Graybug is a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases.

Graybug Vision Reports Full Year 2021 Financial Results and Recent Corporate Developments

Retrieved on: 
Thursday, March 10, 2022
Doctor of Pharmacy, IVT, Safety, AMD, Clinical trial, Disease management, Initiate, VEGF, IPO, Annual report, Private Securities Litigation Reform Act, IND, Therapy, Visual acuity, Sunitinib, U.S. Securities and Exchange Commission, Research, Investment, Investor, Completeness, Form 10-K, Retina, GLOBE, Patient, Ophthalmology, CST, Glaucoma, Technology, COVID-19, Johns Hopkins School of Medicine, Insurance, Forward-looking statement, Pharmaceutical industry, Sintering

BALTIMORE, March 10, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today provided an update on recent corporate developments and reported financial results for the full year ended December 31, 2021.

Key Points: 
  • BALTIMORE, March 10, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today provided an update on recent corporate developments and reported financial results for the full year ended December 31, 2021.
  • Graybug made important progress in advancing its retina (GB-102) and glaucoma (GB-401) programs in 2021.
  • Completed ALTISSIMO Phase 2b trial in wet age-related macular degeneration (wet AMD) Final results confirm unprecedented duration in an aflibercept-controlled clinical trial.
  • Best corrected visual acuity (BCVA) of patients in the GB-102 1mg arm trended lower than aflibercepts, mainly driven by 4 subjects.

HUTCHMED Receives a US$15 million Milestone from AstraZeneca for Initiating Start-up Activities for a Global Phase III Study of ORPATHYS® in Lung Cancer

Retrieved on: 
Monday, March 7, 2022
PFS, TKI, Sunitinib, Society, U.S. Securities and Exchange Commission, New Drug Application, Patient, COVID-19, Disease, AIM, Lung, Lung cancer, Private Securities Litigation Reform Act, Dor, MET, Forward-looking statement, Gene amplification, PK, LinkedIn, GEJ, Large-cell lung carcinoma, Colorectal cancer, ORR, Man, HCM, AstraZeneca, GC, Kidney, Neoplasm, PD-L1, Woman, Sale, American Society of Clinical Oncology, Mutation, NSCLC, Hereditary diffuse gastric cancer, Squamous cell carcinoma, Progression-free survival, Recurrence, HIV disease progression rates, Adenocarcinoma, PRCC, Safety, Growth, ASCO, Cancer, Conference, Hong Kong Stock Exchange, Program, GLOBE, Therapy, Pharmaceutical industry, Savolitinib, EGFR, Lancet, RCC

To date, AstraZeneca has now paid HUTCHMED US$85 million of the total US$140 million in upfront payments, development and first-sale milestones due under the license and collaboration agreement between HUTCHMED and AstraZeneca.

Key Points: 
  • To date, AstraZeneca has now paid HUTCHMED US$85 million of the total US$140 million in upfront payments, development and first-sale milestones due under the license and collaboration agreement between HUTCHMED and AstraZeneca.
  • In 2011, following its discovery and initial development by HUTCHMED, AstraZeneca and HUTCHMED entered a global licensing and collaboration agreement to jointly develop and commercialize savolitinib.
  • Under the current terms of the agreement, a US$15 million milestone payment is triggered by the initiation of start-up activities for the SAFFRON study.
  • Joint development of savolitinib in China is led by HUTCHMED, while AstraZeneca leads development outside of China.

Graybug to Participate in Three Upcoming Medical and Investor Conferences

Retrieved on: 
Thursday, February 3, 2022
Private Securities Litigation Reform Act, Forward-looking statement, Patient, FACS, Doctor of Pharmacy, CT, Johns Hopkins School of Medicine, Durability, Retina, VEGF, Optic nerve, Technology, Partner, Visual acuity, COVID-19, Clinical trial, U.S. Securities and Exchange Commission, Annual report, Glaucoma, GLOBE, Sunitinib, Disease management, Security (finance), Observation, Form 10-K, Conference, MBA, Data analysis, CA, Pharmaceutical industry, MD

The event will be held virtually and in-person at the Grand Hyatt Union Square in San Francisco, CA.

Key Points: 
  • The event will be held virtually and in-person at the Grand Hyatt Union Square in San Francisco, CA.
  • 11th Annual SVB Leerink Global Healthcare Conference Fred Guerard, PharmD, to participate in virtual fireside chat on February 17, 2022, at 9:20 a.m.
  • Graybug is a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve.
  • Founded in 2011 on the basis of technology licensed from the Johns Hopkins University School of Medicine, Graybug has offices in Redwood City, California, and in Baltimore, Maryland.